{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:57:55Z","timestamp":1790449075854,"version":"4.1.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06209-9","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:06:17Z","timestamp":1790399177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights into X-linked Dystonia-Parkinsonism and Spinocerebellar Ataxia\u00a0type\u00a036 Through the Lens of Amyotrophic Lateral Sclerosis\/Frontotemporal Dementia"],"prefix":"10.1007","volume":"63","author":[{"given":"Mansee","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumalya","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi Pramod","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-4308","authenticated-orcid":false,"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"6209_CR1","doi-asserted-by":"publisher","unstructured":"Paulson H (2018) Chapter 9 - repeat expansion diseases. In: Geschwind DH, Paulson HL, Klein C (eds) Neurogenetics, Part I. vol 147. Handbook of clinical neurology, Elsevier, pp 105\u2013123. https:\/\/doi.org\/10.1016\/B978-0-444-63233-3.00009-9","DOI":"10.1016\/B978-0-444-63233-3.00009-9"},{"issue":"9","key":"6209_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41580-021-00382-6","volume":"22","author":"I Malik","year":"2021","unstructured":"Malik I, Kelley CP, Wang ET, Todd PK (2021) Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat Rev Mol Cell Biol 22(9):589\u2013607. https:\/\/doi.org\/10.1038\/s41580-021-00382-6","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"6209_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ajhg.2021.03.011","volume":"108","author":"C Depienne","year":"2021","unstructured":"Depienne C, Mandel JL (2021) 30 years of repeat expansion disorders: what have we learned and what are the remaining challenges? Am J Hum Genet 108(5):764\u2013785. https:\/\/doi.org\/10.1016\/j.ajhg.2021.03.011","journal-title":"Am J Hum Genet"},{"key":"6209_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.843014","author":"M Boivin","year":"2022","unstructured":"Boivin M, Charlet-Berguerand N (2022) Trinucleotide CGG repeat diseases: an expanding field of polyglycine proteins? Front Genet. https:\/\/doi.org\/10.3389\/fgene.2022.843014","journal-title":"Front Genet"},{"issue":"R1","key":"6209_CR5","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1093\/hmg\/ddz138","volume":"28","author":"P Gonzalez-Alegre","year":"2019","unstructured":"Gonzalez-Alegre P (2019) Recent advances in molecular therapies for neurological disease: triplet repeat disorders. Hum Mol Genet 28(R1):R80\u2013R87. https:\/\/doi.org\/10.1093\/hmg\/ddz138","journal-title":"Hum Mol Genet"},{"issue":"7","key":"6209_CR6","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1007\/s00415-024-12435-9","volume":"271","author":"N Riva","year":"2024","unstructured":"Riva N, Domi T, Pozzi L et al (2024) Update on recent advances in amyotrophic lateral sclerosis. J Neurol 271(7):4693\u20134723. https:\/\/doi.org\/10.1007\/s00415-024-12435-9","journal-title":"J Neurol"},{"key":"6209_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.837690","author":"S Lopez","year":"2022","unstructured":"Lopez S, He F (2022) Spinocerebellar ataxia 36: from mutations toward therapies. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2022.837690","journal-title":"Front Genet"},{"issue":"4","key":"6209_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/WCO.0000000000000708","volume":"32","author":"DC Bragg","year":"2019","unstructured":"Bragg DC, Sharma N, Ozelius LJ (2019) X-Linked dystonia-parkinsonism: recent advances. Curr Opin Neurol 32(4):604. https:\/\/doi.org\/10.1097\/WCO.0000000000000708","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"6209_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72(2):245\u2013256. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.011","journal-title":"Neuron"},{"issue":"1","key":"6209_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ajhg.2011.05.015","volume":"89","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi H, Abe K, Matsuura T et al (2011) Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 89(1):121\u2013130. https:\/\/doi.org\/10.1016\/j.ajhg.2011.05.015","journal-title":"Am J Hum Genet"},{"issue":"51","key":"6209_CR11","doi-asserted-by":"publisher","first-page":"E11020","DOI":"10.1073\/pnas.1712526114","volume":"114","author":"DC Bragg","year":"2017","unstructured":"Bragg DC, Mangkalaphiban K, Vaine CA et al (2017) Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proc Natl Acad Sci 114(51):E11020\u2013E11028. https:\/\/doi.org\/10.1073\/pnas.1712526114","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"6209_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ (2023) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22(3):185\u2013212. https:\/\/doi.org\/10.1038\/s41573-022-00612-2","journal-title":"Nat Rev Drug Discov"},{"key":"6209_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1322720","author":"Y Geng","year":"2024","unstructured":"Geng Y, Cai Q (2024) Role of C9orf72 hexanucleotide repeat expansions in ALS\/FTD pathogenesis. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2024.1322720","journal-title":"Front Mol Neurosci"},{"key":"6209_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ijbiomac.2022.12.231","volume":"229","author":"R Sun","year":"2023","unstructured":"Sun R, Guo X, Yang D et al (2023) RNA G-quadruplex in live cells lighted-up by a thiazole orange analogue for SCA36 identification. Int J Biol Macromol 229:724\u2013731. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.12.231","journal-title":"Int J Biol Macromol"},{"issue":"19","key":"6209_CR15","doi-asserted-by":"publisher","first-page":"11571","DOI":"10.1093\/nar\/gkae797","volume":"52","author":"G Nicoletto","year":"2024","unstructured":"Nicoletto G, Terreri M, Maurizio I et al (2024) G-quadruplexes in an SVA retrotransposon cause aberrant TAF1 gene expression in X-linked dystonia parkinsonism. Nucleic Acids Res 52(19):11571\u201311586. https:\/\/doi.org\/10.1093\/nar\/gkae797","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"6209_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neuron.2020.06.025","volume":"107","author":"N Maharjan","year":"2020","unstructured":"Maharjan N, Saxena S (2020) It takes two to tango: DPRs in ALS and SCA36. Neuron 107(2):202\u2013204. https:\/\/doi.org\/10.1016\/j.neuron.2020.06.025","journal-title":"Neuron"},{"issue":"11","key":"6209_CR17","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1002\/mds.29183","volume":"37","author":"CJ Reyes","year":"2022","unstructured":"Reyes CJ, Asano K, Todd PK, Klein C, Rakovic A (2022) Repeat-associated non-AUG translation of AGAGGG repeats that cause X-linked dystonia-parkinsonism. Mov Disord 37(11):2284\u20132289. https:\/\/doi.org\/10.1002\/mds.29183","journal-title":"Mov Disord"},{"key":"6209_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.784833","author":"IS Pasniceanu","year":"2021","unstructured":"Pasniceanu IS, Atwal MS, Souza CDS, Ferraiuolo L, Livesey MR (2021) Emerging mechanisms underpinning neurophysiological impairments in C9ORF72 repeat expansion-mediated amyotrophic lateral sclerosis\/frontotemporal dementia. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2021.784833","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"6209_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13760-022-02144-3","volume":"123","author":"HL Chin","year":"2023","unstructured":"Chin HL, Lin CY, Chou OHI (2023) X-linked dystonia parkinsonism: epidemiology, genetics, clinical features, diagnosis, and treatment. Acta Neurol Belg 123(1):45\u201355. https:\/\/doi.org\/10.1007\/s13760-022-02144-3","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"6209_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1042\/ETLS20230019","volume":"7","author":"JL Read","year":"2023","unstructured":"Read JL, Davies KC, Thompson GC, Delatycki MB, Lockhart PJ (2023) Challenges facing repeat expansion identification, characterisation, and the pathway to discovery. Emerg Top Life Sci 7(3):339\u2013348. https:\/\/doi.org\/10.1042\/ETLS20230019","journal-title":"Emerg Top Life Sci"},{"key":"6209_CR21","doi-asserted-by":"publisher","first-page":"234.e1","DOI":"10.1016\/j.neurobiolaging.2018.09.010","volume":"74","author":"C Fournier","year":"2019","unstructured":"Fournier C, Barbier M, Camuzat A et al (2019) Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging 74:234.e1-234.e8. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.09.010","journal-title":"Neurobiol Aging"},{"issue":"2","key":"6209_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/humu.22244","volume":"34","author":"J van der Zee","year":"2013","unstructured":"van der Zee J, Gijselinck I, Dillen L et al (2013) A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 34(2):363\u2013373. https:\/\/doi.org\/10.1002\/humu.22244","journal-title":"Hum Mutat"},{"issue":"1","key":"6209_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(11)70261-7","volume":"11","author":"I Gijselinck","year":"2012","unstructured":"Gijselinck I, Van Langenhove T, van der Zee J et al (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11(1):54\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(11)70261-7","journal-title":"Lancet Neurol"},{"key":"6209_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.661447","author":"J Smeyers","year":"2021","unstructured":"Smeyers J, Banchi EG, Latouche M (2021) C9ORF72: what it is, what it does, and why it matters. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2021.661447","journal-title":"Front Cell Neurosci"},{"key":"6209_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107503","volume":"223","author":"Q Wang","year":"2022","unstructured":"Wang Q, Zhang C, Liu S et al (2022) Long-read sequencing identified intronic (GGCCTG)n expansion in NOP56 in one SCA36 family and literature review. Clin Neurol Neurosurg 223:107503. https:\/\/doi.org\/10.1016\/j.clineuro.2022.107503","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"6209_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ana.25488","volume":"85","author":"A Westenberger","year":"2019","unstructured":"Westenberger A, Reyes CJ, Saranza G et al (2019) A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. Ann Neurol 85(6):812\u2013822. https:\/\/doi.org\/10.1002\/ana.25488","journal-title":"Ann Neurol"},{"issue":"11","key":"6209_CR27","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1093\/hmg\/ddv064","volume":"24","author":"A Nordin","year":"2015","unstructured":"Nordin A, Akimoto C, Wuolikainen A et al (2015) Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet 24(11):3133\u20133142. https:\/\/doi.org\/10.1093\/hmg\/ddv064","journal-title":"Hum Mol Genet"},{"issue":"3","key":"6209_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000670","volume":"8","author":"S Breevoort","year":"2022","unstructured":"Breevoort S, Gibson S, Figueroa K, Bromberg M, Pulst S (2022) Expanding clinical spectrum of C9ORF72-related disorders and promising therapeutic strategies: a review. Neurol Genet 8(3):e670. https:\/\/doi.org\/10.1212\/NXG.0000000000000670","journal-title":"Neurol Genet"},{"issue":"10","key":"6209_CR29","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1093\/nar\/gkae250","volume":"52","author":"N Kojak","year":"2024","unstructured":"Kojak N, Kuno J, Fittipaldi KE et al (2024) Somatic and intergenerational G4C2 hexanucleotide repeat instability in a human C9orf72 knock-in mouse model. Nucleic Acids Res 52(10):5732\u20135755. https:\/\/doi.org\/10.1093\/nar\/gkae250","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"6209_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40478-022-01349-0","volume":"10","author":"LN Campion","year":"2022","unstructured":"Campion LN, Mejia Maza A, Yadav R et al (2022) Tissue-specific and repeat length-dependent somatic instability of the X-linked dystonia parkinsonism-associated CCCTCT repeat. Acta Neuropathol Commun 10(1):49. https:\/\/doi.org\/10.1186\/s40478-022-01349-0","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"6209_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/brain\/aws069","volume":"135","author":"M Garc\u00eda-Murias","year":"2012","unstructured":"Garc\u00eda-Murias M, Quint\u00e1ns B, Arias M et al (2012) \u2018Costa da Morte\u2019 ataxia is spinocerebellar ataxia 36: clinical and genetic characterization. Brain 135(5):1423. https:\/\/doi.org\/10.1093\/brain\/aws069","journal-title":"Brain"},{"issue":"4","key":"6209_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1212\/WNL.0b013e318260436f","volume":"79","author":"Y Ikeda","year":"2012","unstructured":"Ikeda Y, Ohta Y, Kobayashi H et al (2012) Clinical features of SCA36. Neurology 79(4):333\u2013341. https:\/\/doi.org\/10.1212\/WNL.0b013e318260436f","journal-title":"Neurology"},{"key":"6209_CR33","doi-asserted-by":"publisher","unstructured":"Zou J, Wang F, Gong Z et al (2023) A Chinese SCA36 pedigree analysis of NOP56 expansion region based on long-read sequencing. Front Genet 14. https:\/\/doi.org\/10.3389\/fgene.2023.1110307","DOI":"10.3389\/fgene.2023.1110307"},{"issue":"8","key":"6209_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41580-020-0236-x","volume":"21","author":"D Varshney","year":"2020","unstructured":"Varshney D, Spiegel J, Zyner K, Tannahill D, Balasubramanian S (2020) The regulation and functions of DNA and RNA G-quadruplexes. Nat Rev Mol Cell Biol 21(8):459\u2013474. https:\/\/doi.org\/10.1038\/s41580-020-0236-x","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"6209_CR35","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/biom14101278","volume":"14","author":"F Pan","year":"2024","unstructured":"Pan F, Xu P, Roland C, Sagui C, Weninger K (2024) Structural and dynamical properties of nucleic acid hairpins implicated in trinucleotide repeat expansion diseases. Biomolecules 14(10):1278. https:\/\/doi.org\/10.3390\/biom14101278","journal-title":"Biomolecules"},{"issue":"21","key":"6209_CR36","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jmb.2016.08.031","volume":"429","author":"P Richard","year":"2017","unstructured":"Richard P, Manley JL (2017) R loops and links to human disease. J Mol Biol 429(21):3168\u20133180. https:\/\/doi.org\/10.1016\/j.jmb.2016.08.031","journal-title":"J Mol Biol"},{"issue":"1","key":"6209_CR37","doi-asserted-by":"publisher","first-page":"8272","DOI":"10.1038\/s41467-023-43872-1","volume":"14","author":"F Raguseo","year":"2023","unstructured":"Raguseo F, Wang Y, Li J et al (2023) The ALS\/FTD-related C9orf72 hexanucleotide repeat expansion forms RNA condensates through multimolecular G-quadruplexes. Nat Commun 14(1):8272. https:\/\/doi.org\/10.1038\/s41467-023-43872-1","journal-title":"Nat Commun"},{"issue":"5","key":"6209_CR38","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1021\/acschemneuro.7b00476","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Roland C, Sagui C (2018) Structural and dynamical characterization of DNA and RNA quadruplexes obtained from the GGGGCC and GGGCCT hexanucleotide repeats associated with C9FTD\/ALS and SCA36 diseases. ACS Chem Neurosci 9(5):1104\u20131117. https:\/\/doi.org\/10.1021\/acschemneuro.7b00476","journal-title":"ACS Chem Neurosci"},{"issue":"15","key":"6209_CR39","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.1093\/nar\/gkab609","volume":"49","author":"J Robinson","year":"2021","unstructured":"Robinson J, Raguseo F, Nuccio SP, Liano D, Di Antonio M (2021) DNA G-quadruplex structures: more than simple roadblocks to transcription? Nucleic Acids Res 49(15):8419\u20138431. https:\/\/doi.org\/10.1093\/nar\/gkab609","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"6209_CR40","doi-asserted-by":"publisher","first-page":"9860","DOI":"10.1074\/jbc.C113.452532","volume":"288","author":"K Reddy","year":"2013","unstructured":"Reddy K, Zamiri B, Stanley SYR, Macgregor RB, Pearson CE (2013) The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J Biol Chem 288(14):9860\u20139866. https:\/\/doi.org\/10.1074\/jbc.C113.452532","journal-title":"J Biol Chem"},{"issue":"1","key":"6209_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep01016","volume":"2","author":"P Fratta","year":"2012","unstructured":"Fratta P, Mizielinska S, Nicoll AJ et al (2012) C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci Rep 2(1):1016. https:\/\/doi.org\/10.1038\/srep01016","journal-title":"Sci Rep"},{"issue":"7491","key":"6209_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nature13124","volume":"507","author":"AR Haeusler","year":"2014","unstructured":"Haeusler AR, Donnelly CJ, Periz G et al (2014) C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507(7491):195\u2013200. https:\/\/doi.org\/10.1038\/nature13124","journal-title":"Nature"},{"issue":"4","key":"6209_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.mrl.2022.07.004","volume":"2","author":"C Liu","year":"2022","unstructured":"Liu C, Zhou B, Xu N et al (2022) The parallel tetrameric DNA G-quadruplex formed by the two-repeat C9orf72 GGGGCC sequence in solution. Magn Reson Lett 2(4):196\u2013204. https:\/\/doi.org\/10.1016\/j.mrl.2022.07.004","journal-title":"Magn Reson Lett"},{"issue":"2","key":"6209_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly CJ, Zhang PW, Pham JT et al (2013) RNA Toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80(2):415\u2013428. https:\/\/doi.org\/10.1016\/j.neuron.2013.10.015","journal-title":"Neuron"},{"issue":"17","key":"6209_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713437","volume":"24","author":"M Zalar","year":"2023","unstructured":"Zalar M, Wang B, Plavec J, \u0160ket P (2023) Insight into tetramolecular DNA G-quadruplexes associated with ALS and FTLD: cation interactions and formation of higher-ordered structure. Int J Mol Sci 24(17):13437. https:\/\/doi.org\/10.3390\/ijms241713437","journal-title":"Int J Mol Sci"},{"key":"6209_CR46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neures.2021.03.001","volume":"171","author":"K Hirayanagi","year":"2021","unstructured":"Hirayanagi K, Ozaki H, Tsukagoshi S, Furuta N, Ikeda Y (2021) Porphyrins ameliorate spinocerebellar ataxia type 36 GGCCTG repeat expansion-mediated cytotoxicity. Neurosci Res 171:92\u2013102. https:\/\/doi.org\/10.1016\/j.neures.2021.03.001","journal-title":"Neurosci Res"},{"key":"6209_CR47","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ijbiomac.2022.01.097","volume":"201","author":"J Yi","year":"2022","unstructured":"Yi J, Wan L, Liu Y et al (2022) NMR solution structures of d(GGCCTG)n repeats associated with spinocerebellar ataxia type 36. Int J Biol Macromol 201:607\u2013615. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.01.097","journal-title":"Int J Biol Macromol"},{"issue":"14","key":"6209_CR48","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00018-007-7084-0","volume":"64","author":"J H\u00e4sler","year":"2007","unstructured":"H\u00e4sler J, Samuelsson T, Strub K (2007) Useful \u201cjunk\u201d: Alu RNAs in the human transcriptome. Cell Mol Life Sci 64(14):1793\u20131800. https:\/\/doi.org\/10.1007\/s00018-007-7084-0","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"6209_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43403-3","volume":"9","author":"A Shein","year":"2019","unstructured":"Shein A, Zaikin A, Poptsova M (2019) Recognition of 3\u2032-end L1, Alu, processed pseudogenes, and mRNA stem-loops in the human genome using sequence-based and structure-based machine-learning models. Sci Rep 9(1):7211. https:\/\/doi.org\/10.1038\/s41598-019-43403-3","journal-title":"Sci Rep"},{"key":"6209_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2025.1671906","author":"S Almalki","year":"2025","unstructured":"Almalki S, Salama M, Taylor MJ, Ahmed Z, Tuxworth RI (2025) C9orf72-related amyotrophic lateral sclerosis-frontotemporal dementia and links to the DNA damage response: a systematic review. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2025.1671906","journal-title":"Front Mol Neurosci"},{"issue":"9","key":"6209_CR51","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/nn.4604","volume":"20","author":"C Walker","year":"2017","unstructured":"Walker C, Herranz-Martin S, Karyka E et al (2017) C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat Neurosci 20(9):1225\u20131235. https:\/\/doi.org\/10.1038\/nn.4604","journal-title":"Nat Neurosci"},{"issue":"15","key":"6209_CR52","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/hmg\/ddx170","volume":"26","author":"MA Farg","year":"2017","unstructured":"Farg MA, Konopka A, Soo KY, Ito D, Atkin JD (2017) The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum Mol Genet 26(15):2882\u20132896. https:\/\/doi.org\/10.1093\/hmg\/ddx170","journal-title":"Hum Mol Genet"},{"issue":"7","key":"6209_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115812","volume":"44","author":"L D\u2019Ignazio","year":"2025","unstructured":"D\u2019Ignazio L, Lorenzetti APR, Penney EB et al (2025) A hexamer tandem repeat RNA embedded within an SVA retrotransposon drives R-loop formation and neurodegeneration. Cell Rep 44(7):115812. https:\/\/doi.org\/10.1016\/j.celrep.2025.115812","journal-title":"Cell Rep"},{"issue":"2","key":"6209_CR54","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuron.2020.04.011","volume":"107","author":"ZT McEachin","year":"2020","unstructured":"McEachin ZT, Gendron TF, Raj N et al (2020) Chimeric peptide species contribute to divergent dipeptide repeat pathology in c9ALS\/FTD and SCA36. Neuron 107(2):292-305.e6. https:\/\/doi.org\/10.1016\/j.neuron.2020.04.011","journal-title":"Neuron"},{"key":"6209_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.637548","author":"A Schmitz","year":"2021","unstructured":"Schmitz A, Pinheiro Marques J, Oertig I, Maharjan N, Saxena S (2021) Emerging perspectives on dipeptide repeat proteins in C9ORF72 ALS\/FTD. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2021.637548","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"6209_CR56","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/hmg\/ddu576","volume":"24","author":"M Yamakawa","year":"2015","unstructured":"Yamakawa M, Ito D, Honda T et al (2015) Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD\/ALS. Hum Mol Genet 24(6):1630\u20131645. https:\/\/doi.org\/10.1093\/hmg\/ddu576","journal-title":"Hum Mol Genet"},{"issue":"4","key":"6209_CR57","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","volume":"77","author":"PEA Ash","year":"2013","unstructured":"Ash PEA, Bieniek KF, Gendron TF et al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS. Neuron 77(4):639\u2013646. https:\/\/doi.org\/10.1016\/j.neuron.2013.02.004","journal-title":"Neuron"},{"key":"6209_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00035","author":"BD Freibaum","year":"2017","unstructured":"Freibaum BD, Taylor JP (2017) The role of dipeptide repeats in C9ORF72-related ALS-FTD. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2017.00035","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"6209_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107616","volume":"31","author":"TW Todd","year":"2020","unstructured":"Todd TW, McEachin ZT, Chew J et al (2020) Hexanucleotide repeat expansions in c9FTD\/ALS and SCA36 confer selective patterns of neurodegeneration in vivo. Cell Rep 31(5):107616. https:\/\/doi.org\/10.1016\/j.celrep.2020.107616","journal-title":"Cell Rep"},{"key":"6209_CR60","doi-asserted-by":"publisher","unstructured":"Prado LDGR, Bicalho ICS, Magalh\u00e3es D, Caramelli P, Teixeira AL, de Souza LC (2015) C9ORF72 and the FTD-ALS spectrum: a systematic review of neuroimaging studies. Dement Neuropsychol\u00a09(4):413. https:\/\/doi.org\/10.1590\/1980-57642015DN94000413","DOI":"10.1590\/1980-57642015DN94000413"},{"issue":"4","key":"6209_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/life15040647","volume":"15","author":"M Gonz\u00e1lez-S\u00e1nchez","year":"2025","unstructured":"Gonz\u00e1lez-S\u00e1nchez M, Ram\u00edrez-Exp\u00f3sito MJ, Mart\u00ednez-Martos JM (2025) Pathophysiology, clinical heterogeneity, and therapeutic advances in amyotrophic lateral sclerosis: a comprehensive review of molecular mechanisms, diagnostic challenges, and multidisciplinary management strategies. Life 15(4):647. https:\/\/doi.org\/10.3390\/life15040647","journal-title":"Life"},{"key":"6209_CR62","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2147\/NDT.S127863","volume":"13","author":"FT Gossink","year":"2017","unstructured":"Gossink FT, Vijverberg EG, Krudop W et al (2017) Psychosis in behavioral variant frontotemporal dementia. Neuropsychiatr Dis Treat 13:1099\u20131106. https:\/\/doi.org\/10.2147\/NDT.S127863","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"6209_CR63","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cortex.2010.12.002","volume":"48","author":"CL Stopford","year":"2012","unstructured":"Stopford CL, Thompson JC, Neary D, Richardson AMT, Snowden JS (2012) Working memory, attention, and executive function in Alzheimer\u2019s disease and frontotemporal dementia. Cortex 48(4):429\u2013446. https:\/\/doi.org\/10.1016\/j.cortex.2010.12.002","journal-title":"Cortex"},{"issue":"3","key":"6209_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1474-4422(25)00026-2","volume":"24","author":"S Mizielinska","year":"2025","unstructured":"Mizielinska S, Hautbergue GM, Gendron TF et al (2025) Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics. Lancet Neurol 24(3):261\u2013274. https:\/\/doi.org\/10.1016\/S1474-4422(25)00026-2","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"6209_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jns.2012.10.013","volume":"324","author":"Y Ikeda","year":"2013","unstructured":"Ikeda Y, Ohta Y, Kurata T, Shiro Y, Takao Y, Abe K (2013) Acoustic impairment is a distinguishable clinical feature of Asidan\/SCA36. J Neurol Sci 324(1\u20132):109\u2013112. https:\/\/doi.org\/10.1016\/j.jns.2012.10.013","journal-title":"J Neurol Sci"},{"issue":"11","key":"6209_CR66","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/ene.12491","volume":"21","author":"W Liu","year":"2014","unstructured":"Liu W, Ikeda Y, Hishikawa N, Yamashita T, Deguchi K, Abe K (2014) Characteristic RNA foci of the abnormal hexanucleotide GGCCUG repeat expansion in spinocerebellar ataxia type 36 (Asidan). Eur J Neurol 21(11):1377\u20131386. https:\/\/doi.org\/10.1111\/ene.12491","journal-title":"Eur J Neurol"},{"issue":"6","key":"6209_CR67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.nrl.2014.11.005","volume":"32","author":"M Arias","year":"2017","unstructured":"Arias M, Garc\u00eda-Murias M, Sobrido MJ (2017) Spinocerebellar ataxia 36 (SCA36): \u00abCosta da Morte ataxia\u00bb. Neurologia 32(6):386\u2013393. https:\/\/doi.org\/10.1016\/j.nrl.2014.11.005","journal-title":"Neurologia"},{"issue":"3","key":"6209_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad106","volume":"5","author":"P Acuna","year":"2023","unstructured":"Acuna P, Supnet-Wells ML, Spencer NA et al (2023) Establishing a natural history of X-linked dystonia parkinsonism. Brain Commun 5(3):fcad106. https:\/\/doi.org\/10.1093\/braincomms\/fcad106","journal-title":"Brain Commun"},{"issue":"1","key":"6209_CR69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/lary.27897","volume":"130","author":"PC Song","year":"2020","unstructured":"Song PC, Le H, Acuna P et al (2020) Voice and swallowing dysfunction in X-linked dystonia parkinsonism. Laryngoscope 130(1):171\u2013177. https:\/\/doi.org\/10.1002\/lary.27897","journal-title":"Laryngoscope"},{"key":"6209_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.parkreldis.2021.07.006","volume":"89","author":"AL Zaninotto","year":"2021","unstructured":"Zaninotto AL, de Guzman JK, Stipancic KL et al (2021) Speech and swallowing deficits in X-linked dystonia-parkinsonism. Parkinsonism Relat Disord 89:105\u2013110. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.07.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"6209_CR71","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00702-021-02317-z","volume":"128","author":"RDG Jamora","year":"2021","unstructured":"Jamora RDG, Suratos CTR, Bautista JEC et al (2021) Neurocognitive profile of patients with X-linked dystonia-parkinsonism. J Neural Transm 128(5):671\u2013678. https:\/\/doi.org\/10.1007\/s00702-021-02317-z","journal-title":"J Neural Transm"},{"issue":"4","key":"6209_CR72","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jmb.2005.09.085","volume":"354","author":"H Wang","year":"2005","unstructured":"Wang H, Xing J, Grover D et al (2005) SVA elements: a hominid-specific retroposon family. J Mol Biol 354(4):994\u20131007. https:\/\/doi.org\/10.1016\/j.jmb.2005.09.085","journal-title":"J Mol Biol"},{"issue":"11","key":"6209_CR73","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1101\/gr.093435.109","volume":"19","author":"A Damert","year":"2009","unstructured":"Damert A, Raiz J, Horn AV et al (2009) 5\u2019-Transducing SVA retrotransposon groups spread efficiently throughout the human genome. Genome Res 19(11):1992\u20132008. https:\/\/doi.org\/10.1101\/gr.093435.109","journal-title":"Genome Res"},{"issue":"4","key":"6209_CR74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1515\/medgen-2021-2105","volume":"33","author":"J Pozojevic","year":"2021","unstructured":"Pozojevic J, Cruz JN, Westenberger A (2021) X-linked dystonia-parkinsonism: over and above a repeat disorder. Med Genet Mitteilungsbl Berufsverb Med Genet EV 33(4):319\u2013324. https:\/\/doi.org\/10.1515\/medgen-2021-2105","journal-title":"Med Genet Mitteilungsbl Berufsverb Med Genet EV"},{"issue":"1","key":"6209_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/genes13010126","volume":"13","author":"T L\u00fcth","year":"2022","unstructured":"L\u00fcth T, La\u03b2 J, Schaake S et al (2022) Elucidating hexanucleotide repeat number and methylation within the X-linked dystonia-parkinsonism (XDP)-related SVA retrotransposon in TAF1 with nanopore sequencing. Genes 13(1):126. https:\/\/doi.org\/10.3390\/genes13010126","journal-title":"Genes"},{"issue":"10","key":"6209_CR76","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41594-024-01320-8","volume":"31","author":"V Horv\u00e1th","year":"2024","unstructured":"Horv\u00e1th V, Garza R, J\u00f6nsson ME et al (2024) Mini-heterochromatin domains constrain the cis-regulatory impact of SVA transposons in human brain development and disease. Nat Struct Mol Biol 31(10):1543\u20131556. https:\/\/doi.org\/10.1038\/s41594-024-01320-8","journal-title":"Nat Struct Mol Biol"},{"key":"6209_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gde.2017.01.005","volume":"44","author":"N Zhang","year":"2017","unstructured":"Zhang N, Ashizawa T (2017) RNA toxicity and foci formation in microsatellite expansion diseases. Curr Opin Genet Dev 44:17\u201329. https:\/\/doi.org\/10.1016\/j.gde.2017.01.005","journal-title":"Curr Opin Genet Dev"},{"issue":"19","key":"6209_CR78","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1093\/hmg\/ddr299","volume":"20","author":"M Wojciechowska","year":"2011","unstructured":"Wojciechowska M, Krzyzosiak WJ (2011) Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 20(19):3811\u20133821. https:\/\/doi.org\/10.1093\/hmg\/ddr299","journal-title":"Hum Mol Genet"},{"issue":"12","key":"6209_CR79","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrneurol.2013.244","volume":"9","author":"H Wood","year":"2013","unstructured":"Wood H (2013) C9orf72 RNA foci\u2014a therapeutic target for ALS and FTD? Nat Rev Neurol 9(12):659\u2013659. https:\/\/doi.org\/10.1038\/nrneurol.2013.244","journal-title":"Nat Rev Neurol"},{"key":"6209_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105055","volume":"145","author":"ZT McEachin","year":"2020","unstructured":"McEachin ZT, Parameswaran J, Raj N, Bassell GJ, Jiang J (2020) RNA-mediated toxicity in C9orf72 ALS and FTD. Neurobiol Dis 145:105055. https:\/\/doi.org\/10.1016\/j.nbd.2020.105055","journal-title":"Neurobiol Dis"},{"key":"6209_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00711","author":"V Kumar","year":"2017","unstructured":"Kumar V, Hasan GM, Hassan MI (2017) Unraveling the role of RNA mediated toxicity of C9orf72 repeats in C9-FTD\/ALS. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2017.00711","journal-title":"Front Neurosci"},{"issue":"5","key":"6209_CR82","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.cell.2018.02.011","volume":"172","author":"T Aneichyk","year":"2018","unstructured":"Aneichyk T, Hendriks WT, Yadav R et al (2018) Dissecting the causal mechanism of X-linked dystonia-parkinsonism by integrating genome and transcriptome assembly. Cell 172(5):897-909.e21. https:\/\/doi.org\/10.1016\/j.cell.2018.02.011","journal-title":"Cell"},{"key":"6209_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.783624","author":"BC Benson","year":"2021","unstructured":"Benson BC, Shaw PJ, Azzouz M, Highley JR, Hautbergue GM (2021) Proteinopathies as hallmarks of impaired gene expression, proteostasis and mitochondrial function in amyotrophic lateral sclerosis. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2021.783624","journal-title":"Front Neurosci"},{"issue":"5796","key":"6209_CR84","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130\u2013133. https:\/\/doi.org\/10.1126\/science.1134108","journal-title":"Science"},{"issue":"3","key":"6209_CR85","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351(3):602\u2013611. https:\/\/doi.org\/10.1016\/j.bbrc.2006.10.093","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"6209_CR86","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/hmg\/ddy174","volume":"27","author":"T Nonaka","year":"2018","unstructured":"Nonaka T, Masuda-Suzukake M, Hosokawa M et al (2018) C9ORF72 dipeptide repeat poly-GA inclusions promote intracellular aggregation of phosphorylated TDP-43. Hum Mol Genet 27(15):2658\u20132670. https:\/\/doi.org\/10.1093\/hmg\/ddy174","journal-title":"Hum Mol Genet"},{"issue":"10","key":"6209_CR87","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1093\/brain\/awy241","volume":"141","author":"DA Solomon","year":"2018","unstructured":"Solomon DA, Stepto A, Au WH et al (2018) A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-\u03b1 mediates C9orf72-related neurodegeneration. Brain 141(10):2908\u20132924. https:\/\/doi.org\/10.1093\/brain\/awy241","journal-title":"Brain"},{"key":"6209_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1124907","author":"K Davidson","year":"2023","unstructured":"Davidson K, Pickering AM (2023) The proteasome: a key modulator of nervous system function, brain aging, and neurodegenerative disease. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2023.1124907","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"6209_CR89","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/jnen\/nlad078","volume":"82","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Nelson SCK, Viera Ortiz AP, Lee EB, Fairman R (2023) C9orf72 proline-arginine dipeptide repeats disrupt the proteasome and perturb proteolytic activities. J Neuropathol Exp Neurol 82(11):901\u2013910. https:\/\/doi.org\/10.1093\/jnen\/nlad078","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"6209_CR90","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00018-022-04518-5","volume":"79","author":"M Pu","year":"2022","unstructured":"Pu M, Tai Y, Yuan L et al (2022) The contribution of proteasomal impairment to autophagy activation by C9orf72 poly-GA aggregates. Cell Mol Life Sci 79(9):501. https:\/\/doi.org\/10.1007\/s00018-022-04518-5","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"6209_CR91","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.cell.2017.12.030","volume":"172","author":"Q Guo","year":"2018","unstructured":"Guo Q, Lehmer C, Mart\u00ednez-S\u00e1nchez A et al (2018) In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell 172(4):696-705.e12. https:\/\/doi.org\/10.1016\/j.cell.2017.12.030","journal-title":"Cell"},{"issue":"1","key":"6209_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00365-9","volume":"15","author":"NS Andrade","year":"2020","unstructured":"Andrade NS, Ramic M, Esanov R et al (2020) Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS\/FTD. Mol Neurodegener 15(1):13. https:\/\/doi.org\/10.1186\/s13024-020-00365-9","journal-title":"Mol Neurodegener"},{"issue":"9","key":"6209_CR93","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41582-018-0047-2","volume":"14","author":"R Balendra","year":"2018","unstructured":"Balendra R, Isaacs AM (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14(9):544\u2013558. https:\/\/doi.org\/10.1038\/s41582-018-0047-2","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"6209_CR94","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.neuron.2016.09.015","volume":"92","author":"R Lopez-Gonzalez","year":"2016","unstructured":"Lopez-Gonzalez R, Lu Y, Gendron TF et al (2016) Poly(GR) in C9ORF72-related ALS\/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron 92(2):383\u2013391. https:\/\/doi.org\/10.1016\/j.neuron.2016.09.015","journal-title":"Neuron"},{"issue":"10","key":"6209_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101897","volume":"11","author":"J Jim\u00e9nez-Villegas","year":"2022","unstructured":"Jim\u00e9nez-Villegas J, Kirby J, Mata A et al (2022) Dipeptide repeat pathology in C9orf72-ALS is associated with redox, mitochondrial and NRF2 pathway imbalance. Antioxidants (Basel) 11(10):1897. https:\/\/doi.org\/10.3390\/antiox11101897","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"6209_CR96","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae282","volume":"6","author":"J Rivers-Auty","year":"2024","unstructured":"Rivers-Auty J, Hoyle C, Pointer A et al (2024) C9orf72 dipeptides activate the NLRP3 inflammasome. Brain Commun 6(5):fcae282. https:\/\/doi.org\/10.1093\/braincomms\/fcae282","journal-title":"Brain Commun"},{"issue":"2","key":"6209_CR97","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72(2):257\u2013268. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.010","journal-title":"Neuron"},{"issue":"3","key":"6209_CR98","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1086\/512129","volume":"80","author":"S Makino","year":"2007","unstructured":"Makino S, Kaji R, Ando S et al (2007) Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet 80(3):393\u2013406. https:\/\/doi.org\/10.1086\/512129","journal-title":"Am J Hum Genet"},{"issue":"6125","key":"6209_CR99","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1126\/science.1232927","volume":"339","author":"K Mori","year":"2013","unstructured":"Mori K, Weng SM, Arzberger T et al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS. Science 339(6125):1335\u20131338. https:\/\/doi.org\/10.1126\/science.1232927","journal-title":"Science"},{"issue":"1","key":"6209_CR100","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran H, Moazami MP, Yang H et al (2022) Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med 28(1):117\u2013124. https:\/\/doi.org\/10.1038\/s41591-021-01557-6","journal-title":"Nat Med"},{"issue":"47","key":"6209_CR101","doi-asserted-by":"publisher","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","volume":"110","author":"C Lagier-Tourenne","year":"2013","unstructured":"Lagier-Tourenne C, Baughn M, Rigo F et al (2013) Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci 110(47):E4530\u2013E4539. https:\/\/doi.org\/10.1073\/pnas.1318835110","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"6209_CR102","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41593-019-0455-7","volume":"22","author":"SB Yamada","year":"2019","unstructured":"Yamada SB, Gendron TF, Niccoli T et al (2019) RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats. Nat Neurosci 22(9):1383\u20131388. https:\/\/doi.org\/10.1038\/s41593-019-0455-7","journal-title":"Nat Neurosci"},{"issue":"6","key":"6209_CR103","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41593-019-0396-1","volume":"22","author":"LD Goodman","year":"2019","unstructured":"Goodman LD, Prudencio M, Kramer NJ et al (2019) Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD. Nat Neurosci 22(6):863\u2013874. https:\/\/doi.org\/10.1038\/s41593-019-0396-1","journal-title":"Nat Neurosci"},{"issue":"9","key":"6209_CR104","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1474-4422(24)00216-3","volume":"23","author":"LH van den Berg","year":"2024","unstructured":"van den Berg LH, Rothstein JD, Shaw PJ et al (2024) Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. Lancet Neurol 23(9):901\u2013912. https:\/\/doi.org\/10.1016\/S1474-4422(24)00216-3","journal-title":"Lancet Neurol"},{"issue":"23","key":"6209_CR105","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1016\/j.cell.2025.07.045","volume":"188","author":"ZT McEachin","year":"2025","unstructured":"McEachin ZT, Chung M, Stratton SA et al (2025) Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS. Cell 188(23):6424-6435.e17. https:\/\/doi.org\/10.1016\/j.cell.2025.07.045","journal-title":"Cell"},{"issue":"3","key":"6209_CR106","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.molmed.2023.12.003","volume":"30","author":"SH Van Daele","year":"2024","unstructured":"Van Daele SH, Masrori P, Van Damme P, Van Den Bosch L (2024) The sense of antisense therapies in ALS. Trends Mol Med 30(3):252\u2013262. https:\/\/doi.org\/10.1016\/j.molmed.2023.12.003","journal-title":"Trends Mol Med"},{"key":"6209_CR107","unstructured":"Wave life sciences announces topline results from phase 1b\/2a FOCUS-C9 study of WVE-004 for C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia - wave life sciences.\u00a0https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-topline-results-phase-1b2a-focus-c9. Accessed 17 July 2026"},{"issue":"1","key":"6209_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02652-3","volume":"147","author":"JD Rothstein","year":"2023","unstructured":"Rothstein JD, Baskerville V, Rapuri S et al (2023) G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS\/FTD induced pluripotent stem cell derived neurons. Acta Neuropathol (Berl) 147(1):1. https:\/\/doi.org\/10.1007\/s00401-023-02652-3","journal-title":"Acta Neuropathol (Berl)"},{"issue":"12","key":"6209_CR109","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A et al (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387(12):1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"issue":"2","key":"6209_CR110","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaneurol.2025.4946","volume":"83","author":"TM Miller","year":"2026","unstructured":"Miller TM, Cudkowicz ME, Shaw PJ et al (2026) Long-term tofersen in SOD1 amyotrophic lateral sclerosis. JAMA Neurol 83(2):115\u2013125. https:\/\/doi.org\/10.1001\/jamaneurol.2025.4946","journal-title":"JAMA Neurol"},{"issue":"4","key":"6209_CR111","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar M, Wuu J, Andersen PM et al (2022) Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19(4):1248\u20131258. https:\/\/doi.org\/10.1007\/s13311-022-01237-4","journal-title":"Neurotherapeutics"},{"issue":"10494","key":"6209_CR112","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","volume":"405","author":"NA Shneider","year":"2025","unstructured":"Shneider NA, Harms MB, Korobeynikov VA et al (2025) Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet 405(10494):2075\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(25)00513-6","journal-title":"Lancet"},{"key":"6209_CR113","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","volume":"16","author":"R Martier","year":"2019","unstructured":"Martier R, Liefhebber JM, Garc\u00eda-Osta A et al (2019) Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids 16:26\u201337. https:\/\/doi.org\/10.1016\/j.omtn.2019.02.001","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"6209_CR114","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","volume":"21","author":"KD Foust","year":"2013","unstructured":"Foust KD, Salazar DL, Likhite S et al (2013) Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21(12):2148\u20132159. https:\/\/doi.org\/10.1038\/mt.2013.211","journal-title":"Mol Ther"},{"key":"6209_CR115","doi-asserted-by":"publisher","unstructured":"Borel F, Gernoux G, Sun H\u00a0et al (2018) Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med\u00a010(465). https:\/\/doi.org\/10.1126\/scitranslmed.aau6414","DOI":"10.1126\/scitranslmed.aau6414"},{"issue":"4","key":"6209_CR116","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/gt.2017.9","volume":"24","author":"GM Thomsen","year":"2017","unstructured":"Thomsen GM, Alkaslasi M, Vit JP et al (2017) Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects. Gene Ther 24(4):245\u2013252. https:\/\/doi.org\/10.1038\/gt.2017.9","journal-title":"Gene Ther"},{"key":"6209_CR117","unstructured":"Exclusive: Biogen calls it quits on AAV gene therapy, again. Endpoints News.\u00a0https:\/\/endpoints.news\/biogen-calls-it-quits-on-aav-gene-therapy-again\/. Accessed 17 July 2026"},{"key":"6209_CR118","unstructured":"Incorvaia D (2025) Vertex discontinues AAV vector research for gene therapies.\u00a0https:\/\/www.fiercebiotech.com\/biotech\/vertex-discontinues-aav-vector-research-gene-therapies\u00a0. Accessed 17 July 2026"},{"key":"6209_CR119","unstructured":"Jackson M (2025) Pfizer cuts last AAV gene therapy program by taking Beqvez off the market. Insights. https:\/\/insights.citeline.com\/scrip\/business\/strategy\/pfizer-cuts-last-aav-gene-therapy-program-by-taking-beqvez-off-the-market-M2I2Y4SJAVH65LHL2HTTQOBSKY\/. Accessed 17 July 2026"},{"key":"6209_CR120","unstructured":"JCR Pharmaceuticals and Takeda Pharmaceuticals announce discontinuation of gene therapy collaboration. https:\/\/www.businesswire.com\/news\/home\/20231220750926\/en\/JCR-Pharmaceuticals-and-Takeda-Pharmaceuticals-Announce-Discontinuation-of-Gene-Therapy-Collaboration. Accessed 17 July 2026"},{"issue":"5","key":"6209_CR121","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","volume":"33","author":"AM Nisanov","year":"2025","unstructured":"Nisanov AM, Rivera de Jes\u00fas JA, Schaffer DV (2025) Advances in AAV capsid engineering: integrating rational design, directed evolution and machine learning. Mol Ther 33(5):1937\u20131945. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.056","journal-title":"Mol Ther"},{"issue":"5","key":"6209_CR122","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.molmed.2023.02.004","volume":"29","author":"WM Pardridge","year":"2023","unstructured":"Pardridge WM (2023) Brain gene therapy with Trojan horse lipid nanoparticles. Trends Mol Med 29(5):343\u2013353. https:\/\/doi.org\/10.1016\/j.molmed.2023.02.004","journal-title":"Trends Mol Med"},{"key":"6209_CR123","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.reth.2025.07.009","volume":"30","author":"H Khan","year":"2025","unstructured":"Khan H, Riaz H, Ahmed A et al (2025) CRISPR\/Cas9 a genomic engineering technology for treatment in ALS mouse models. Regen Ther 30:575. https:\/\/doi.org\/10.1016\/j.reth.2025.07.009","journal-title":"Regen Ther"},{"issue":"1","key":"6209_CR124","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s42003-021-01942-4","volume":"4","author":"HX Deng","year":"2021","unstructured":"Deng HX, Zhai H, Shi Y et al (2021) Efficacy and long-term safety of CRISPR\/Cas9 genome editing in the SOD1-linked mouse models of ALS. Commun Biol 4(1):396. https:\/\/doi.org\/10.1038\/s42003-021-01942-4","journal-title":"Commun Biol"},{"issue":"1","key":"6209_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55548-5","volume":"16","author":"TX McCallister","year":"2025","unstructured":"McCallister TX, Lim CKW, Singh M et al (2025) A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS\/FTD. Nat Commun 16(1):460. https:\/\/doi.org\/10.1038\/s41467-024-55548-5","journal-title":"Nat Commun"},{"issue":"1","key":"6209_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33332-7","volume":"13","author":"KE Meijboom","year":"2022","unstructured":"Meijboom KE, Abdallah A, Fordham NP et al (2022) CRISPR\/Cas9-mediated excision of ALS\/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat Commun 13(1):6286. https:\/\/doi.org\/10.1038\/s41467-022-33332-7","journal-title":"Nat Commun"},{"key":"6209_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102057","volume":"34","author":"SK Chen","year":"2023","unstructured":"Chen SK, Hawley ZCE, Zavodszky MI et al (2023) Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection. Mol Ther Nucleic Acids 34:102057. https:\/\/doi.org\/10.1016\/j.omtn.2023.102057","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"6209_CR128","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"H Costa Verdera","year":"2020","unstructured":"Costa Verdera H, Kuranda K, Mingozzi F (2020) AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28(3):723\u2013746. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.010","journal-title":"Mol Ther"},{"key":"6209_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y (2023) Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157","journal-title":"Front Bioeng Biotechnol"},{"issue":"5","key":"6209_CR130","doi-asserted-by":"publisher","first-page":"10","DOI":"10.15252\/emmm.201607054","volume":"9","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Lehmer C, Michaelsen M et al (2017) Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med 9(5):10. https:\/\/doi.org\/10.15252\/emmm.201607054","journal-title":"EMBO Mol Med"},{"issue":"2","key":"6209_CR131","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910919","volume":"12","author":"Q Zhou","year":"2019","unstructured":"Zhou Q, Mareljic N, Michaelsen M et al (2019) Active poly\u2010GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol Med 12(2):EMMM201910919. https:\/\/doi.org\/10.15252\/emmm.201910919","journal-title":"EMBO Mol Med"},{"issue":"1","key":"6209_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30387-4","volume":"13","author":"G Krishnan","year":"2022","unstructured":"Krishnan G, Raitcheva D, Bartlett D et al (2022) Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS\/FTD. Nat Commun 13(1):2799. https:\/\/doi.org\/10.1038\/s41467-022-30387-4","journal-title":"Nat Commun"},{"issue":"49","key":"6209_CR133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123487119","volume":"119","author":"M Jambeau","year":"2022","unstructured":"Jambeau M, Meyer KD, Hruska-Plochan M et al (2022) Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease. Proc Natl Acad Sci 119(49):e2123487119. https:\/\/doi.org\/10.1073\/pnas.2123487119","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"6209_CR134","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.neuron.2019.11.007","volume":"105","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, Montrasio F, Pattamatta A et al (2020) Antibody therapy targeting RAN proteins rescues C9 ALS\/FTD phenotypes in C9orf72 mouse model. Neuron 105(4):645-662.e11. https:\/\/doi.org\/10.1016\/j.neuron.2019.11.007","journal-title":"Neuron"},{"key":"6209_CR135","unstructured":"Alector Inc. (2025) A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in C9orf72-associated amyotrophic lateral sclerosis. https:\/\/clinicaltrials.gov\/study\/NCT05053035. Accessed 17 July 2026"},{"issue":"31","key":"6209_CR136","doi-asserted-by":"publisher","first-page":"18591","DOI":"10.1073\/pnas.2005748117","volume":"117","author":"T Zu","year":"2020","unstructured":"Zu T, Guo S, Bardhi O et al (2020) Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS\/FTD mice. Proc Natl Acad Sci U S A 117(31):18591\u201318599. https:\/\/doi.org\/10.1073\/pnas.2005748117","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"6209_CR137","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1093\/brain\/awae109","volume":"147","author":"S Babu","year":"2024","unstructured":"Babu S, Nicholson KA, Rothstein JD et al (2024) Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial. Brain 147(9):2998\u20133008. https:\/\/doi.org\/10.1093\/brain\/awae109","journal-title":"Brain"},{"issue":"11","key":"6209_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11111543","volume":"11","author":"M Ramic","year":"2021","unstructured":"Ramic M, Andrade NS, Rybin MJ et al (2021) Epigenetic small molecules rescue nucleocytoplasmic transport and DNA damage phenotypes in C9ORF72 ALS\/FTD. Brain Sci 11(11):1543. https:\/\/doi.org\/10.3390\/brainsci11111543","journal-title":"Brain Sci"},{"issue":"9","key":"6209_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094276","volume":"26","author":"ZZ Chong","year":"2025","unstructured":"Chong ZZ, Souayah N (2025) Targeting gene C9orf72 pathogenesis for amyotrophic lateral sclerosis. Int J Mol Sci 26(9):4276. https:\/\/doi.org\/10.3390\/ijms26094276","journal-title":"Int J Mol Sci"},{"issue":"13","key":"6209_CR140","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.3390\/ijms26136268","volume":"26","author":"M Cattaneo","year":"2025","unstructured":"Cattaneo M, Giagnorio E, Lauria G, Marcuzzo S (2025) Therapeutic approaches for C9ORF72-related ALS: current strategies and future horizons. Int J Mol Sci 26(13):6268. https:\/\/doi.org\/10.3390\/ijms26136268","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6209_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00525-z","volume":"17","author":"P Masrori","year":"2022","unstructured":"Masrori P, Beckers J, Gossye H, Van Damme P (2022) The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS\/FTD. Mol Neurodegener 17(1):22. https:\/\/doi.org\/10.1186\/s13024-022-00525-z","journal-title":"Mol Neurodegener"},{"key":"6209_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00068","author":"D Petrov","year":"2017","unstructured":"Petrov D, Mansfield C, Moussy A, Hermine O (2017) ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2017.00068","journal-title":"Front Aging Neurosci"},{"key":"6209_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1054006","author":"J Jiang","year":"2020","unstructured":"Jiang J, Wang Y, Deng M (2020) New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.1054006","journal-title":"Front Pharmacol"},{"issue":"2","key":"6209_CR144","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","volume":"39","author":"MK Jaiswal","year":"2019","unstructured":"Jaiswal MK (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39(2):733\u2013748. https:\/\/doi.org\/10.1002\/med.21528","journal-title":"Med Res Rev"},{"key":"6209_CR145","doi-asserted-by":"publisher","unstructured":"Paganoni S, Berry JD, Quintana M et al (n.d.) Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. https:\/\/doi.org\/10.1002\/ana.26285","DOI":"10.1002\/ana.26285"},{"key":"6209_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1636303","author":"T Roy","year":"2025","unstructured":"Roy T, Al-Chalabi A, Iacoangeli A, Al Khleifat A (2025) Biomarkers in ALS trials: from discovery to clinical utility. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2025.1636303","journal-title":"Front Neurosci"},{"key":"6209_CR147","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.omtn.2017.06.017","volume":"8","author":"K Matsuzono","year":"2017","unstructured":"Matsuzono K, Imamura K, Murakami N et al (2017) Antisense oligonucleotides reduce RNA foci in spinocerebellar ataxia 36 patient iPSCs. Mol Ther - Nucleic Acids 8:211\u2013219. https:\/\/doi.org\/10.1016\/j.omtn.2017.06.017","journal-title":"Mol Ther - Nucleic Acids"},{"issue":"9","key":"6209_CR148","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s10038-024-01260-7","volume":"69","author":"T Morikawa","year":"2024","unstructured":"Morikawa T, Miura S, Uchiyama Y et al (2024) Hexanucleotide repeat expansion in SCA36 reduces the expression of genes involved in ribosome biosynthesis and protein translation. J Hum Genet 69(9):411\u2013416. https:\/\/doi.org\/10.1038\/s10038-024-01260-7","journal-title":"J Hum Genet"},{"key":"6209_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1610884","volume":"29","author":"S Zhao","year":"2023","unstructured":"Zhao S, Zhang D, Liu S, Huang J (2023) The roles of NOP56 in cancer and SCA36. Pathol Oncol Res 29:1610884. https:\/\/doi.org\/10.3389\/pore.2023.1610884","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"6209_CR150","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/mds.27441","volume":"33","author":"A Rakovic","year":"2018","unstructured":"Rakovic A, Domingo A, Gr\u00fctz K et al (2018) Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism. Mov Disord 33(7):1108\u20131118. https:\/\/doi.org\/10.1002\/mds.27441","journal-title":"Mov Disord"},{"issue":"4","key":"6209_CR151","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","volume":"19","author":"BD Boros","year":"2022","unstructured":"Boros BD, Schoch KM, Kreple CJ, Miller TM (2022) Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeutics 19(4):1145\u20131158. https:\/\/doi.org\/10.1007\/s13311-022-01247-2","journal-title":"Neurotherapeutics"},{"issue":"12","key":"6209_CR152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243655","volume":"15","author":"T Petrozziello","year":"2020","unstructured":"Petrozziello T, Dios AM, Mueller KA et al (2020) SVA insertion in X-linked dystonia parkinsonism alters histone H3 acetylation associated with TAF1 gene. PLoS ONE 15(12):e0243655. https:\/\/doi.org\/10.1371\/journal.pone.0243655","journal-title":"PLoS ONE"},{"issue":"33","key":"6209_CR153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401217121","volume":"121","author":"JL Rosenkrantz","year":"2024","unstructured":"Rosenkrantz JL, Brandorff JE, Raghib S et al (2024) ZNF91 is an endogenous repressor of the molecular phenotype associated with X-linked dystonia-parkinsonism (XDP). Proc Natl Acad Sci U S A 121(33):e2401217121. https:\/\/doi.org\/10.1073\/pnas.2401217121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6209_CR154","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1353-8020(02)00042-1","volume":"9","author":"LV Lee","year":"2002","unstructured":"Lee LV, Maranon E, Demaisip C et al (2002) The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Parkinsonism Relat Disord 9(1):29\u201338. https:\/\/doi.org\/10.1016\/s1353-8020(02)00042-1","journal-title":"Parkinsonism Relat Disord"},{"key":"6209_CR155","doi-asserted-by":"publisher","unstructured":"Hawthorne SC, Valentine YA, Arora A, Lim F (2025) Advancing rare disease clinical trials on an international scale: barriers and emerging solutions. MIT Sci Policy Rev\u00a06. https:\/\/doi.org\/10.38105\/spr.cb0t0jkorb","DOI":"10.38105\/spr.cb0t0jkorb"},{"issue":"2","key":"6209_CR156","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/mus.28442","volume":"72","author":"BA Harkey","year":"2025","unstructured":"Harkey BA, Distefano S, Pagliaro JA et al (2025) Operational development and launch of an adaptive platform trial in amyotrophic lateral sclerosis: processes and learnings from the first four regimens of the HEALEY ALS Platform Trial. Muscle Nerve 72(2):294\u2013305. https:\/\/doi.org\/10.1002\/mus.28442","journal-title":"Muscle Nerve"},{"issue":"8","key":"6209_CR157","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881. https:\/\/doi.org\/10.1136\/jnnp-2018-320106","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"6209_CR158","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40478-018-0564-7","volume":"6","author":"N Sakae","year":"2018","unstructured":"Sakae N, Bieniek KF, Zhang YJ et al (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun 6(1):63. https:\/\/doi.org\/10.1186\/s40478-018-0564-7","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"6209_CR159","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mds.28305","volume":"36","author":"J Al Ali","year":"2021","unstructured":"Al Ali J, Vaine CA, Shah S et al (2021) TAF1 transcripts and neurofilament light chain as biomarkers for X-linked dystonia-parkinsonism. Mov Disord 36(1):206\u2013215. https:\/\/doi.org\/10.1002\/mds.28305","journal-title":"Mov Disord"},{"key":"6209_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105032","volume":"144","author":"T Petrozziello","year":"2020","unstructured":"Petrozziello T, Mills AN, Vaine CA et al (2020) Neuroinflammation and histone H3 citrullination are increased in X-linked dystonia parkinsonism post-mortem prefrontal cortex. Neurobiol Dis 144:105032. https:\/\/doi.org\/10.1016\/j.nbd.2020.105032","journal-title":"Neurobiol Dis"},{"issue":"1","key":"6209_CR161","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","volume":"95","author":"M Benatar","year":"2020","unstructured":"Benatar M, Zhang L, Wang L et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59\u2013e69. https:\/\/doi.org\/10.1212\/WNL.0000000000009559","journal-title":"Neurology"},{"issue":"4","key":"6209_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100607","volume":"3","author":"TF Gendron","year":"2022","unstructured":"Gendron TF, Heckman MG, White LJ et al (2022) Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med 3(4):100607. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100607","journal-title":"Cell Rep Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06209-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06209-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06209-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:02:21Z","timestamp":1790445741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06209-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6209"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06209-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT\u00a0for language improvement and to find suitable synonyms.  The content produced by the tool was subsequently reviewed, modified and edited by the authors, who take full responsibility for the final content of the publication.","order":3,"name":"Ethics","label":"Declaration of Generative AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"926"}}